Question Bank › Second engine igniting off the first

Second engine igniting off the first

Second engine igniting off the first: an unplanned-for adjacent revenue stream has started paying, and management is now

Calls Tested
434
Answered YES
11
Hit Rate
2.5%
rare by design

Illumina, Inc. (ILMN) — this company's answers

NO on the Q1 2018 call 2018-04-24 A
The model's full reasoning — Q1 2018 call → NOWe need answer YES or NO based on transcript. Need determine if management describes second distinct way of making money emerged from existing operations, already generating real paying business, and being deliberately grown. Let's parse transcript. Company Illumina. Core business sequencing instruments/consumables, microarrays. They have services. Need identify second avenue that grew out of first. Possible candidates: Helix? But Helix is separate investment, not from operations? They mention Helix losses, tax benefit. Not second avenue. Microarray business? It's existing segment, not second from sequencing. Sequencing services? They have service and other revenue, including genotyping services, sequencing services, instrument maintenance contracts. Is that a second avenue? It grew from existing capabilities? But it's part of their business. They mention "Microarray service revenue doubled" and "sequencing services" but not as distinct new avenue. Oncology collaborations with pharma: companion diagnostics. They are partnering to create distributable companion diagnostics. This is a new revenue avenue? They mention milestone payments associated with recently announced oncology collaborations included in sequencing and other revenue. This is a second way of making money from existing technology? They are leveraging their sequencing technology and assays to develop companion diagnostics with pharma. It is distinct from selling instruments/consumables. It is already generating? They said no revenue impact in Q1, but guidance includes milestone payments. They are deliberately pursuing more partnerships. But is it "already generating real paying business today"? They said "Milestone payments associated with our recently announced oncology collaborations. These will be included in sequencing and other revenue." And "we haven’t recognized any milestones or contributions from them. We will going forward as these start to take off." So not yet paying? They are signed deals, but no revenue yet. So not "already generating real paying business today" in Q1. They expect future. So NO. Another candidate: Consumer genomics / DTC market driving microarray services. That's existing business. Another: "Illumina will continue to be an important enabler and innovator of sequencing broadly through the system and consumables we bring to market.

← Back to the full ILMN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that a SECOND, DISTINCT WAY OF MAKING MONEY has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional revenue avenue that grew out of what the company already does rather than a separate diversification - AND that this second avenue is ALREADY GENERATING REAL PAYING BUSINESS today while management is now deliberately putting effort or resources behind growing it? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent phenomenon with both halves present as a present-tense reality: (1) A SECOND EARNING AVENUE THAT GREW OUT OF THE FIRST. Management identifies an additional, distinguishable stream of business that arose from something the company already built or does - for example: monetizing a capability, technology, process, data, byproduct, or infrastructure that was originally created to serve the core business; the company's existing product or asset base opening a different kind of revenue (services on an installed base, licensing what it developed for itself, selling to a different side of its market, a spin-out offering born from internal tools, a byproduct or secondary output now being sold in its own right); or an offering originally built for one purpose now being sold as its own line of business. What matters is the ORIGIN - the second avenue leverages what already exists inside the company - and the DISTINCTNESS - management talks about it as its own stream of business, not just more sales of the same thing to the same buyers. (2) IT IS PAYING TODAY AND BEING FED. Management indicates that this second avenue is already producing real current revenue, orders, contracts, or paying customers in the recent period - actual money changing hands now, however small relative to the core - AND describes deliberate current effort to grow it: dedicating people, investment, capacity, or organizational focus to it; signing further deals in it; building it out; or explicitly treating it as a growth avenue the company is now pursuing on purpose. Answer NO if the company describes only one way of making money, however strong or fast-growing. NO if the additional avenue is only an idea, plan, pilot without paying customers, or an opportunity management says it could pursue someday. NO if the 'second stream' is ordinary cross-selling, upselling, product-line extensions, or new versions sold to the same customers in the same basic way. NO if the second business came chiefly from acquiring an unrelated company rather than emerging from the company's own operations. NO if management mentions the additional stream only in passing without conveying that it is real, paying, and being deliberately grown. NO if the company is a conglomerate or multi-segment business simply reporting its usual several segments. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
M Macy's, Inc. Q4 2022 2023-03-02 D
CMLS Cumulus Media Inc. Q3 2022 2022-10-28 D
GDRX GoodRx Holdings, Inc. Q2 2022 2022-08-08 F
SOPH SOPHiA GENETICS SA Q4 2021 2022-03-15 C
SLQT SelectQuote, Inc. Q2 2022 2022-02-07 F
LC LendingClub Corporation Q4 2021 2022-01-26 A
IRBT iRobot Corporation Q3 2021 2021-10-28 D
T AT&T Inc. Q3 2018 2018-10-24 C+
LRN Stride, Inc. Q1 2019 2018-10-23 B
MITK Mitek Systems, Inc. Q4 2017 2017-11-07 C+
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C

How the model reasoned

LRN · Q1 2019 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows career readiness as a distinct second revenue avenue that emerged directly from the existing MPS business: students already enrolled in Managed Public Schools are being moved into career readiness programs (over 5,000 students), and the initiative is built on the same platform, curriculum, and student base. Management explicitly describes it as a “career readiness line of business” and “robust career readiness business” that is already generating paying enrollments today while they are deliberately investing resources—dedicated executives, reallocation of funds, and plans to drive a major portion of next year’s enrollment growth.
M · Q4 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Macy’s Marketplace is explicitly described as a distinct new revenue avenue that emerged directly from their existing e-commerce operations and customer base (macys.com, cross-shoppers, and omnichannel platform). Jeff Gennette states it “captures incremental sales opportunity,” “drives a larger average order value,” “allows us to quickly move into new and adjacent categories without inventory risk,” and “attracts a new younger customer,” while management is actively scaling it by adding 2,000 brands in 2023 and launching Bloomingdale’s marketplace in the back half.
GDRX · Q2 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Pharma Manufacturer Solutions is the second distinct revenue avenue that emerged from GoodRx’s existing operations. Trevor explicitly states: “Our distinct ability to reach both consumers and providers continues to be recognized by manufacturers as evidenced by the strong growth.” This capability originated from the core prescription-transactions platform and user base 3 years earlier (when other offerings were only ~5% of revenue). In Q2 2022 it generated $26.6 million (102% YoY growth) and is already producing real paying business.

More from the question bank

Event-dense runwayThe leak is fixed: the company is keeping whBet-the-company financing already spent on hManagement is buying/committing capital at aScarcity of the company's own outputDemand pull is outrunning the plan for one sAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.